Eric Whitman, MD
Medical Director, Office of Grants and ResearchAtlantic Health System Inc
Eric Whitman, MD, is a Medical Director of the Office of Grants and Research for Atlantic Health System in Morristown, New Jersey. He is a board certified General Surgeon with fellowship training in surgical oncology. He specializes in melanoma care, endocrine and oncologic surgery. Dr. Whitman is also the founding Director of the Atlantic Health Melanoma Center, a clinical and research Center of Excellence within the Carol G. Simon Cancer Center of Morristown Memorial Hospital and Overlook Hospital. He specializes in endocrine and oncologic surgery, with particular emphasis in melanoma care and minimally-invasive endocrine surgery for diseases of the thyroid, parathyroid, and adrenal glands. Dr. Whitman has an active surgical practice and participates in multiple research studies to treat melanoma, with particular interest in novel combinations of immunotherapeutic, chemotherapeutic, and targeted agents. (This is me - Update Profile)
| 2007 - 2007 | Medical Director of Cancer Center Mountainside Hospital |
|---|---|
| 2006 - present | Medical Director, Office of Grants and Research Atlantic Health System Inc |
| 2004 - present | Founding Director of Melanoma Center Atlantic Health System |
| 2004 - 2007 | Chairman/Admin Director Mountainside Hospital |
| 1998 - 2004 | Partner, CIO Suburban Surgical Associates |
| 1992 - 1998 | Assistant Professor Washington University |
GLG Study Groups with Eric Whitman, MD(?)
| Study Group Name | Members |
|---|---|
| Skin Cancer Oncologists (US) | 111 |
| Physicians who Treat Malignant Melanoma (US) | 156 |
| Oncologists (US) | 2248 |
| Nexavar Prescribers: Oncologists | 67 |
GLG NewsSM
Analyses by Eric Whitman, MD(?)
Oncophage is an autologous (or derived directly from a patient's own tumor cells) vaccine that may promote the generation of an effective anti-tumor immune response when re-injected into patients. Trials in melanoma and renal cell cancer failed to meet their primary endpoints and approval has not been...
The Data Safety Monitoring Board halted the Phase III randomized open label trial comparing the Pfizer anti-CTLA4 antibody, tremelimumab, to "standard" (and generally ineffective) chemotherapy for metastatic melanoma. The Board has reported that there is no statistical difference between the primary...
This drug, which has just entered Phase I testing, is very interesting because it combines IL-12, which has shown both activity and significant toxicity, with a targeting antibody. Hopefully, this targeting antibody will minimize the toxicity of IL-12 on or in normal tissues.
The failure of this study has wide ranging implications for Pfizer and other melanoma trials. This drug, which only a few years ago caused much excitement in the melanoma oncology community, failed to show any survival benefit in this Phase III trial, when compared to standard, but generally ineffective,...
GLG InstituteSM Seminars with Eric Whitman, MD(?)
View all GLG InstituteSM Seminars in Healthcare
Request a project with Eric Whitman, MD
Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms